For research use only
| Cat No. | ABC-TC0655 |
| Product Type | Human Breast Cancer Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃ |
| Source Organ | Breast |
| Disease | Adenocarinoma |
| Product Code | MDA_MB_436; MDA MB 436; MDA-Mb-436; MDA-MB436; MDAMB436; MDA-436; MDA436; MB436; MD Anderson-Metastatic Breast-436 |
MDA-MB-436 BRCA1-mutated TNBC cells with spindle-polygonal morphology grow rapidly, show p53 and KRAS mutations, metastatic to lungs and liver in mice.
MDA-MB-436 is a human triple-negative breast cancer (TNBC) cell line derived from the pleural effusion of a 43-year-old Caucasian female with adenocarcinoma. These cells exhibit pleomorphic, spindle- to polygonal-shaped morphology with mesenchymal features. They grow rapidly, and form adherent monolayers. Genetically, MDA-MB-436 harbors a BRCA1 splice site mutation (5396⁺1G>A) with loss of the remaining allele, and also contains p53 and KRAS mutations. Cytogenetic analysis shows complex chromosomal abnormalities with aneuploidy. The cell line is tumorigenic in immunodeficient mice, forming primary tumors and metastasizing primarily to lungs and liver. Immunophenotyping reveals expression of E-cadherin, tubulin, and vimentin. MDA-MB-436 is extensively used to model BRCA1-deficient TNBC and assess targeted therapies.
| Product Code | MDA_MB_436; MDA MB 436; MDA-Mb-436; MDA-MB436; MDAMB436; MDA-436; MDA436; MB436; MD Anderson-Metastatic Breast-436 |
| Species | Human |
| Cat.No | ABC-TC0655 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃ |
| Source Organ | Breast |
| Disease | Adenocarinoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Breast Cancer Cell Lines |
MDA-MB-436 serves as a model to explore the effect of novel drugs or existing agents on breast cancer patients, and determine growth factors driving tumor growth and potential targets for a novel therapeutic strategy for TNBCs. This cell line can also be used to study the pathogenesis of breast cancer.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
